BS PHARM KOREA Expands INHILO+ Market Through Clinical Evaluations and Partnerships
News provided byBS PHARM KOREA · 2 min read
SEOUL, South Korea, BS PHARM KOREA is intensifying its market development efforts for INHILO+, its Dual-Molecular HA skin booster, through a combination of clinical evaluations, domestic distribution partnerships, and ongoing collaboration with healthcare professionals. The company's latest initiatives build on existing clinical data, a partnership with Dongkook Pharmaceutical, and an ongoing clinical evaluation program in South Korea.
INHILO+ is a dual-molecular hyaluronic acid (HA) skin booster, formulated with 48 mg of cross-linked HA in a 2 mL syringe. It combines 24 mg of high molecular weight HA with 24 mg of low molecular weight HA. The high molecular weight HA is designed to enhance moisture retention and structural support, while the low molecular weight HA provides greater diffusion, creating a more comprehensive skin quality improvement approach.
"INHILO+ represents our commitment to professional aesthetic product development through innovative formulation concepts, robust clinical evaluations, and strategic partnerships with industry leaders and healthcare professionals," said a representative from BS PHARM KOREA.
The product's clinical data are supported by a manufacturer-sponsored study involving 55 subjects. The study evaluated INHILO+ alongside a comparable control product, measuring self-assessments of wrinkle improvement and overall aesthetic enhancement at Weeks 2, 12, and 24. Among the subjects, 85.2% reported improvement at Week 2, 67.9% at Week 12, and 55.8% at Week 24. These findings underscore the effectiveness of the Dual-Molecular HA formulation.
In February 2026, BS PHARM KOREA partnered with Dongkook Pharmaceutical to expand INHILO+’s domestic market presence in South Korea. This collaboration leverages Dongkook Pharmaceutical’s established distribution network to ensure broader accessibility of INHILO+ within the Korean professional aesthetic market. The partnership marks an important commercial milestone for INHILO+.
BS PHARM KOREA is also enhancing its clinical insights through an ongoing evaluation program. The program, conducted in collaboration with medical professionals, uses standardized treatment and follow-up conditions to observe skin quality-related parameters and participant outcomes in professional aesthetic practice. This initiative aims to generate additional clinical insights and support continued professional collaboration and evidence-based communication around INHILO+.
As part of its international market development, BS PHARM KOREA plans to introduce INHILO+ to healthcare professionals and industry partners at Dubai Derma 2026, an event taking place from September 8 to 10 in Dubai, United Arab Emirates. The company will present the product’s Dual-Molecular HA concept and engage with prospective partners from international markets. BS PHARM KOREA will also share updates from the ongoing clinical evaluation as follow-up assessments progress.
BS PHARM KOREA continues to support global markets through portfolio development, clinical collaboration, and participation in international medical aesthetics congresses. The company maintains long-term partnerships with distributors worldwide to ensure the long-term development of INHILO+.
The company's comprehensive approach to market development highlights its dedication to advancing professional aesthetic products and meeting the evolving needs of healthcare professionals and consumers.